Compare IMAB & BRIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.